8-K - InMed Pharmaceuticals Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

InMed Pharmaceuticals filed a prospectus supplement on April 3, 2026, to sell common shares worth up to $1,213,648 under its existing At The Market Offering Agreement with H.C. Wainwright & Co.

Key Takeaways

1The Company may sell common shares with an aggregate sales value of up to $1,213,648.

2Sales will be conducted through H.C. Wainwright & Co., LLC acting as sales agent under the ATM Agreement.

3The offering utilizes the effective shelf Registration Statement on Form S-3 (File No. 333-294503).

4Common shares issued will be validly issued, fully paid, and non-assessable.

Current Report Details

Event Type

Other Event

Exhibits Only

Disclosure

Voluntary

Variant

8-K

Items Reported

8.01

Other Events.** ** ** As previously reported, InMed Pharmaceuticals Inc. (the “Company”) entered into an At The Market Offering Agreement dated April 7, 2022, a

Other Event

9.01

Financial Statements and Exhibits** (d) Exhibits. Exhibit No.: 5.1 | Description: Opinion of Norton Rose Fulbright Canada LLP regarding legality of securities b

Exhibits Only

Transaction Details

Material Agreement

Agreement: At The Market Offering Agreement
Parties: InMed Pharmaceuticals Inc., H.C. Wainwright & Co., LLC

•Agreement dated April 7, 2022, as amended on June 27, 2024.
•Aggregate sales value of common shares up to $1,213,648.
•Prospectus supplement filed on April 3, 2026.
•Shares issued pursuant to Form S-3 (File No. 333-294503) declared effective on March 30, 2026.

Exhibits (2)

5.1

OPINION OF NORTON ROSE FULBRIGHT CANADA LLP REGARDING LEGALITY OF SECURITIES BEING REGISTERED

8-K

CURRENT REPORT